VERZENIO Trademark

Trademark Overview

On Tuesday, August 23, 2016, a trademark application was filed for VERZENIO with the United States Patent and Trademark Office. The USPTO has given the VERZENIO trademark a serial number of 87147864. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Thursday, September 5, 2024. This trademark is owned by Eli Lilly and Company. The VERZENIO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer
verzenio

General Information

Serial Number87147864
Word MarkVERZENIO
Filing DateTuesday, August 23, 2016
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateThursday, September 5, 2024
Registration Number5429204
Registration DateTuesday, March 20, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 13, 2016

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, August 29, 2016
Primary Code005
First Use Anywhere DateFriday, October 6, 2017
First Use In Commerce DateFriday, October 6, 2017

Trademark Owner History

Party NameEli Lilly and Company
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285
Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285
Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events

Event DateEvent Description
Monday, August 29, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 26, 2016NEW APPLICATION ENTERED
Tuesday, July 18, 2017SOU EXTENSION 1 FILED
Tuesday, November 1, 2016ASSIGNED TO EXAMINER
Tuesday, November 1, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 23, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 13, 2016PUBLISHED FOR OPPOSITION
Tuesday, December 13, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 7, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, March 9, 2017TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, March 9, 2017ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, July 18, 2017SOU TEAS EXTENSION RECEIVED
Tuesday, August 1, 2017SOU EXTENSION 1 GRANTED
Friday, February 9, 2018STATEMENT OF USE PROCESSING COMPLETE
Tuesday, August 1, 2017CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 2, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 22, 2018SOU TEAS EXTENSION RECEIVED
Monday, January 22, 2018SOU EXTENSION 2 FILED
Monday, January 22, 2018SOU EXTENSION 2 GRANTED
Wednesday, January 24, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, February 2, 2018TEAS STATEMENT OF USE RECEIVED
Friday, February 2, 2018USE AMENDMENT FILED
Friday, February 16, 2024TEAS SECTION 8 & 15 RECEIVED
Thursday, September 5, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, September 5, 2024REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Thursday, September 5, 2024NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Saturday, February 10, 2018ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, February 13, 2018NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, March 20, 2018REGISTERED-PRINCIPAL REGISTER
Monday, March 20, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

Related Keywords

verzenio pharmaceutical preparations cancer namely treatment